Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an update) and Progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205:e18–47.

Article  PubMed  PubMed Central  Google Scholar 

Podolanczuk AJ, Thomson CC, Remy-Jardin M, Richeldi L, Martinez FJ, Kolb M, et al. Idiopathic Pulmonary Fibrosis: state of the art for 2023. Eur Respir J. 2023;61:2200957.

Article  PubMed  Google Scholar 

Richeldi L, Collard HR, Jones MG. Idiopathic Pulmonary Fibrosis. The Lancet. 2017;389:1941–52.

Article  Google Scholar 

Kolb M, Bondue B, Pesci A, Miyazaki Y, Song JW, Bhatt NY, et al. Acute exacerbations of progressive-fibrosing interstitial lung Diseases. Eur Respir Rev. 2018;27:180071.

Article  PubMed  PubMed Central  Google Scholar 

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44–68.

Article  PubMed  Google Scholar 

du Bois RM. An earlier and more confident diagnosis of Idiopathic Pulmonary Fibrosis. Eur Respiratory Rev. 2012;21:141–6.

Article  Google Scholar 

Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, et al. Acute exacerbations of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2007;176:636–43.

Article  PubMed  Google Scholar 

King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of Pirfenidone in patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370:2083–92.

Article  PubMed  Google Scholar 

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370:2071–82.

Article  PubMed  Google Scholar 

Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020;587:555–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khor YH. Antifibrotic therapy for Idiopathic Pulmonary Fibrosis. Chest. 2021;160:1589–91.

Article  CAS  PubMed  Google Scholar 

Bonniaud P, Fabre A, Frossard N, Guignabert C, Inman M, Kuebler WM, et al. Optimising experimental research in Respiratory Diseases: an ERS statement. Eur Respir J. 2018;51:1702133.

Article  PubMed  Google Scholar 

Atkins CP, Loke YK, Wilson AM. Outcomes in Idiopathic Pulmonary Fibrosis: a meta-analysis from placebo controlled trials. Respir Med. 2014;108:376–87.

Article  CAS  PubMed  Google Scholar 

Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194:265–75.

Article  CAS  PubMed  Google Scholar 

Kondoh Y, Taniguchi H, Ebina M, Azuma A, Ogura T, Taguchi Y, et al. Risk factors for acute exacerbation of Idiopathic Pulmonary Fibrosis – extended analysis of pirfenidone trial in Japan. Respiratory Invest. 2015;53:271–8.

Article  Google Scholar 

Jenkins RG, Moore BB, Chambers RC, Eickelberg O, Königshoff M, Kolb M, et al. An official American thoracic Society Workshop Report: Use of Animal models for the Preclinical Assessment of potential therapies for pulmonary fibrosis. Am J Respir Cell Mol Biol. 2017;56:667–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Juarez MM, Chan AL, Norris AG, Morrissey BM, Albertson TE. Acute exacerbation of Idiopathic Pulmonary fibrosis—a review of current and novel pharmacotherapies. J Thorac Disease. 2015;7:21.

Google Scholar 

Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, et al. Acute exacerbations in the INPULSIS trials of nintedanib in Idiopathic Pulmonary Fibrosis. Eur Respir J. 2017;49:1601339.

Article  PubMed  Google Scholar 

Song JW, Hong S-B, Lim C-M, Koh Y, Kim DS. Acute exacerbation of Idiopathic Pulmonary Fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:356–63.

Article  CAS  PubMed  Google Scholar 

Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, et al. Patients with Idiopathic Pulmonary Fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med. 2013;187:768–75.

Article  PubMed  PubMed Central  Google Scholar 

Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, et al. Baseline KL-6 predicts increased risk for acute exacerbation of Idiopathic Pulmonary Fibrosis. Respir Med. 2014;108:1031–9.

Article  PubMed  Google Scholar 

Kishaba T, Nei Y, Momose M, Nagano H, Yamashiro S. Clinical characteristics based on the New Criteria of Acute Exacerbation in patients with Idiopathic Pulmonary Fibrosis. Eurasian J Med. 2018;50:6–10.

Article  PubMed  PubMed Central  Google Scholar 

Cao M, Gu L, Guo L, Liu M, Wang T, Zhang J, et al. Elevated expression of growth differentiation Factor-15 is Associated with Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Front Immunol. 2022;13:891448.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao M, Swigris JJ, Wang X, Cao M, Qiu Y, Huang M, et al. Plasma leptin is elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Mediat Inflamm. 2016;2016:1–7.

Article  CAS  Google Scholar 

Jain M, Budinger GRS, Lo A, Urich D, Rivera SE, Ghosh AK, et al. Leptin promotes fibroproliferative Acute Respiratory Distress Syndrome by inhibiting peroxisome proliferator–activated Receptor-γ. Am J Respir Crit Care Med. 2011;183:1490–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanguy J, Pommerolle L, Garrido C, Kolb M, Bonniaud P, Goirand F, et al. Extracellular heat shock proteins as therapeutic targets and biomarkers in fibrosing interstitial Lung Diseases. IJMS. 2021;22:9316.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Radwanska A, Cottage CT, Piras A, Overed-Sayer C, Sihlbom C, Budida R, et al. Increased expression and accumulation of GDF15 in IPF extracellular matrix contribute to fibrosis. JCI Insight. 2022;7:e153058.

Article  PubMed  PubMed Central  Google Scholar 

Moss BJ, Ryter SW, Rosas IO. Pathogenic mechanisms underlying Idiopathic Pulmonary Fibrosis. Annu Rev Pathol Mech Dis. 2022;17:515–46.

Article  CAS  Google Scholar 

Yanagihara T, Sato S, Upagupta C, Kolb M. What have we learned from basic science studies on Idiopathic Pulmonary Fibrosis? Eur Respir Rev. 2019;28:190029.

Article  PubMed  PubMed Central  Google Scholar 

Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3:349–63.

Article  CAS  PubMed  Google Scholar 

Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE. Baseline BAL Neutrophilia predicts early mortality in Idiopathic Pulmonary Fibrosis. Chest. 2008;133:226–32.

Article  CAS  PubMed  Google Scholar 

Cui H, Xie N, Banerjee S, Ge J, Jiang D, Dey T, et al. Lung myofibroblasts promote macrophage profibrotic activity through lactate-induced histone lactylation. Am J Respir Cell Mol Biol. 2021;64:115–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med. 2020;383:958–68.

Article  CAS  PubMed  Google Scholar 

Yanagihara T, Chong SG, Gholiof M, Lipson KE, Zhou Q, Scallan C et al. Connective-Tissue Growth Factor (CTGF/CCN2) Contributes to TGF-β1-Induced Lung Fibrosis [Internet]. Cell Biology; 2020 Jul. https://doi.org/10.1101/2020.07.04.187492.

Liu GY, Budinger GRS, Dematte JE. Advances in the management of Idiopathic Pulmonary Fibrosis and Progressive pulmonary fibrosis. BMJ. 2022;377:e066354.

Article  PubMed  Google Scholar 

Kishore A, Petrek M. Roles of macrophage polarization and macrophage-derived miRNAs in Pulmonary Fibrosis. Front Immunol. 2021;12:678457.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moyé S, Bormann T, Maus R, Sparwasser T, Sandrock I, Prinz I, et al. Regulatory T cells limit Pneumococcus-Induced Exacerbation of Lung Fibrosis in mice. JI. 2020;204:2429–38.

Google Scholar 

Lehmann M, Korfei M, Mutze K, Klee S, Skronska-Wasek W, Alsafadi HN, et al. Senolytic Drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo. Eur Respir J. 2017;50:1602367.

Article  PubMed  PubMed Central  Google Scholar 

Yanagihara T, Scallan C, Ask K, Kolb MRJ. Emerging therapeutic targets for Idiopathic Pulmonary Fibrosis: preclinical progress and therapeutic implications. Expert Opin Ther Targets. 2021;25:939–48.

Article  CAS  PubMed